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We have previously reported that overexpression of human insulin-like growth factor binding pro-
tein (IGFBP)-1 in mice leads to vascular insulin sensitization, increased nitric oxide bioavailability, 
reduced atherosclerosis, and enhanced vascular repair, and in the setting of obesity improves glu-
cose tolerance. Human studies suggest that low levels of IGFBP-1 are permissive for the develop-
ment of diabetes and cardiovascular disease. Here we seek to determine whether loss of IGFBP-1 
plays a causal role in the predisposition to cardiometabolic disease. Metabolic phenotyping was 
performed in transgenic mice with homozygous knockout of IGFBP-1. This included glucose, insulin, 
and insulin-like growth factor I tolerance testing under normal diet and high-fat feeding conditions. 
Vascular phenotyping was then performed in the same mice using vasomotor aortic ring studies, flow 
cytometry, vascular wire injury, and angiogenesis assays. These were complemented with vascular 
phenotyping of IGFBP-1 overexpressing mice. Metabolic phenotype was similar in IGFBP-1 knockout 
and wild-type mice subjected to obesity. Deletion of IGFBP-1 inhibited endothelial regeneration fol-
lowing injury, suggesting that IGFBP-1 is required for effective vascular repair. Developmental angio-
genesis was unaltered by deletion or overexpression of IGFBP-1. Recovery of perfusion following hind 
limb ischemia was unchanged in mice lacking or overexpressing IGFBP-1; however, overexpression 
of IGFBP-1 stimulated hindlimb perfusion and angiogenesis in insulin-resistant mice. These findings 
provide new insights into the role of IGFBP-1 in metabolic and vascular pathophysiology. Irrespective 
of whether loss of IGFBP-1 plays a causal role in the development of cardiometabolic disorders, 
increasing IGFBP-1 levels appears effective in promoting neovascularization in response to ischemia.
© Endocrine Society 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, 
distribution, and reproduction in any medium, provided the original work is properly cited.
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The hormone insulin and related peptides insulin-like growth factors (IGFs) have diverse 
actions in mammalian physiology. The family of insulin-like growth factor binding proteins 
(IGFBPs) bind IGFs with high affinity and confer temporal and spatial regulation to IGF 
bioactivity [1]. Several members of the IGFBP family also exert cellular effects independent 
of IGF binding and have been identified as putative signaling molecules implicated in a 
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range of physiological processes [2]. Recently, important roles of other members of the IGF 
axis, particularly the IGF binding proteins, have become apparent in obesity, diabetes, and 
cardiovascular disease [3].
IGFBP-1 is a 30-kDa protein, derived mainly from the liver. Under normal conditions, 
changes in plasma insulin concentrations form the primary mechanisms by which IGFBP-1 
levels are regulated via insulin response elements in the IGFBP-1 promoter region, which 
confers insulin inhibition of IGFBP-1 expression [4, 5]. There is a negative correlation be-
tween IGFBP-1 and biomarkers of cardiovascular disease such as blood pressure, body mass 
index (BMI), waist/hip ratio, and fasting insulin levels [6–8], and in prospective studies 
reduced IGFBP-1 levels strongly predict the long-term development of diabetes [9–11] and 
of fatal coronary heart disease independently of other risk factors [12]. Cross-sectional data 
also support an association between low IGFBP-1 levels, cardiovascular risk, and subclin-
ical atherosclerosis [6, 13, 14]. Collectively, these data suggest that low levels of IGFBP-1 
are permissive for the development of both diabetes and cardiovascular disease.
We have previously reported that human IGFBP-1, when overexpressed in mice, leads 
to vascular insulin sensitization; increased nitric bioavailability; reduced atherosclerosis 
[15]; and enhanced vascular repair [16]. In the setting of obesity, we found that IGFBP-1 
enhanced whole-body glucose tolerance and insulin sensitivity through interaction of its 
RGD domain with cell surface integrin receptors [17]. Although these overexpression studies 
provide persuasive evidence for a putative therapeutic role of IGFBP-1, they are unable to 
delineate the role of IGFBP-1 in normal physiology. To examine whether the presence of 
IGFBP-1 is obligatory to maintain metabolic and vascular homeostasis, it is necessary to 
employ a loss-of-function approach in mice with deletion of IGFBP-1.
Several members of the IGFBP family have now been ascribed modulatory roles in vas-
cular endothelial pathophysiology [18]. By influencing functional properties of endothelial 
cells, IGFBPs may confer either stimulatory or inhibitory influences on angiogenesis [19]. 
Although these effects are well reported for IGFBP-2, -3, -4, -5, and -6, the potential influ-
ence of IGFBP-1 on angiogenesis has not been studied.
In this report we undertook metabolic and vascular phenotyping in IGFBP-1-knockout 
(IGFBP-1-KO) mice to determine whether IGFBP-1 is an obligatory player in normal phys-
iology. We also examined the effects of IGFBP-1 on developmental and ischemia-driven an-
giogenesis in IGFBP-1-KO and IGFBP-1-overexpressing mice.
Material and Methods
Animal husbandry
IGFBP-1-KO mice [20–22] (Jackson Laboratory Stock Id 005248) and IGFBP-1-transgenic 
(IGFBP-1-tg) mice (Jackson Laboratory Stock Id 008221) were purchased from the Jackson 
Laboratory and the colonies maintained at the University of Leeds. IRKO mice hemizygous 
for knockout of the insulin receptor were originally obtained from the Mouse Mammalian 
Genetics Unit at MRC Harwell, UK [21, 22]. IRKO × IGFBP-1 mice were generated by 
crossing IGFBP-tg males with IRKO females. The protocol was approved by the University 
of Leeds Ethics Committee (A275) and all experiments were carried out under the authority 
of UK Home Office Licenses PPL 70/8115 and P144DD0D6 and were performed on male 
mice only from the age of 8 weeks, unless otherwise stated. Cages were maintained in hu-
midity- (55%) and temperature-controlled (22°C) conditions with a 12-hour light/dark cycle. 
To induce obesity, 8 week old male mice were fed a high-fat diet for 8 weeks (Research Diets, 
D12492). Mice were genotyped by Transnetyx (Cordova, TN).
In vivo metabolic studies
Metabolic profiling was performed using glucose, insulin, and IGF-I tolerance tests. Mice 
were fasted for 16 hours prior to the glucose tolerance test or 2 hours prior to insulin and 
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IGF-I tolerance tests. Blood glucose was measured using a hand-held Glucose Meter (Accu-
Chek Aviva) taken from the tail vein. An intraperitoneal injection of glucose (1 mg/g), insulin 
(Actrapid; Novo Nordisk, Bagsvaerd, Denmark) (0.75 IU/kg) or IGF-I (Gropep) (0.75 µg/g) 
was performed. Glucose concentration was measured at 30-minute intervals for 2 hours 
from the point of glucose/insulin/IGF-I administration. Mice were not restrained between 
measurements.
Histological assessment of liver
Samples for histology were fixed in 4% paraformaldehyde (PFA) for at least 24 hours, be-
fore processing in ethanol and embedding in paraffin. Five micrometer sections were taken. 
After drying, slides were stained with hematoxylin and eosin.
For assessment of nonalcoholic fatty liver disease (NAFLD) in sections of murine liver, a 
validated rodent NAFLD scoring system was used [23], which takes into account micro and 
macrosteatosis, inflammation, and hypertrophy. Each sample was assessed by at least two 
independent verifiers and the average score per sample taken.
Arterial injury
A small incision was made in the midthigh to permit isolation of the femoral artery. 
Following an arteriotomy made using iris scissors (World-Precision Instruments, Sarasota, 
FL), a 0.014-inch-diameter angioplasty guide wire with tapered tip (Hi-torque Cross-it XT, 
Abbott-Vascular, Abbott, IL) was introduced. The angioplasty guide wire was advanced 
3 cm, and 3 passages were performed per mouse, resulting in complete arterial denudation 
as demonstrated in pilot studies in vessels harvested at day 0. The guide wire was removed 
and the suture was tightened rapidly. The vessel was then ligated, and the skin was closed 
with a continuous suture. The contralateral artery underwent an identical sham operation, 
without passage of the wire. Animals received postoperative analgesia with buprenorphine 
(0.25 mg/kg).
Mice were anesthetized 5 days after wire injury, and 50 μL of 0.5% Evans blue dye injected 
into the inferior vena cava. The mice were perfused/fixed with 4% paraformaldehyde in 
phosphate-buffered saline (PBS) before the femoral arteries (injured and uninjured) were 
harvested. The vessels were opened longitudinally. The areas stained and unstained in 
blue were measured in a 5-mm injured segment beginning 5 mm distal to the aortic bifur-
cation, and the percentage areas were calculated using ImageProPlus7.0 software (Media 
Cybernetics, Bethesda, MD) [16, 24, 25].
Vascular function
Vasomotor function was assessed in aortic rings of 12-week-old mice, as previously 
described [26]. The thoracic aorta was harvested and divided into 5-mm rings. These rings 
were mounted in separate chambers of an organ bath containing Krebs–Henseleit buffer 
(composition in mmol/L: NaCl 119, KCl 4.7, KH2PO4 1.18, NaHCO325, MgSO4 1.19, CaCl2 
2.5, and glucose 11.0) and perfused with 95% O2/5% CO2. Passive tension was increased 
gradually to 3  g and equilibrated to stabilize rings before commencing experiments. 
Relaxation responses to cumulative addition of acetylcholine (1 nmol/L to 100 μmol/L) were 
first assessed after preconstriction with 300 nmol/L of the vasoconstrictor phenylephrine 
(PE). A cumulative dose–response to PE (1 nmol/L to 100 μmol/L) was then performed. 
Finally, the relaxation response to sodium nitroprusside (SNP) (0.01 nmol/L to 100 μmol/L) 
was assessed to examine endothelium-independent vasodilation. Relaxation responses are 
expressed as percentage decrement in preconstricted tension. Chambers were washed with 
Krebs–Henseleit buffer and rings equilibrated back to 3 g of tension between additions of 
each substrate.
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Flow cytometry
Whole blood underwent red blood cell lysis (BD PharmLyseTM). Cells were washed and 
resuspended in PBS containing 0.5% bovine serum albumin (BSA) (Sigma-Aldrich) and 
2 mM ethylenediamine tetra-acetate (EDTA) (Sigma-Aldrich). Fc receptors were blocked 
with a CD16/32 FcR Blocking Reagent (Miltenyi Biotec, 130-092-575) for 10 minutes at 
4°C. Samples were then incubated with anti-CD45-VioBlue (Miltenyi Biotec, 130-110-
802) [27], anti-CD11b-FITC (Miltenyi Biotec, 130-081-201) [28], anti-Ly6G-PE (Miltenyi 
Biotec, 130-107-913) [29], and anti-Ly6C-APC (eBioscience, 17-5932-82) [30] for 10 
minutes at 4°C, according to the manufacturer’s protocol. Stained cells were washed in 
PBS containing 0.5% BSA and 2 mM EDTA. Samples were analyzed by flow cytometry 
(CytoFLEX S, Beckman Coulter). Leukocytes were identified based on typical light scatter 
properties, with further gating to define CD45+ leukocytes, CD45+CD11b+ myeloid cells, 
CD45+CD11b+Ly6G-Ly6Chi inflammatory monocytes, CD45+CD11b+Ly6G-Ly6Clow repara-
tive monocytes, CD45+CD11b+Ly6GhiLy6Chi neutrophils. Data were scaled to cells/mL of 
blood.
Retinal angiogenesis
To determine the effect of IGFBP-1 on developmental angiogenesis, a retinal angiogenesis 
assay was used, as previously described [31]. Briefly, IGFBP-1-KO and IGFBP-1-tg and 
their respective wild-type littermate control P5 male and female pups were euthanized, 
eyes harvested, and eye balls were fixed for 2 hours at room temperature in 4% PFA and 
left in PBS at 4°C until the retinas were dissected. Retinas were stained using Isolectin 
B4-Alexa-488 (Thermo Scientific, I21411), mounted with ProLong Gold (Thermo Scientific, 
P10144), and imaged using an LSM700 confocal microscope.
All image analysis was performed blinded by 2 independent individuals; averages were 
taken of both results. The angiogenic criteria were radial outgrowth defined as distance from 
the outer ring of the optical disk to the vascular front, taking a mean of 3 measurements 
per segment of each retina; branching points (in a 200 µm × 200 µm square) in 6 to 8 areas 
spread across the retina and the mean calculated; vessel density % of the vasculature in the 
peripheral part of the retina; tip cells defined as the number/100 µm of the vascular front 
and the mean calculated over 3 areas per image, and filopodia defined as the number/tip 
cell) from 2/3 tip cells per image and the mean calculated.
Hindlimb ischemia
Hindlimb ischemia was used as an experimental model of pathological angiogenesis, as pre-
viously described [32]. Briefly, mice were anesthetized with isoflurane (2.5–5%) before the 
left femoral artery was exposed, dissected free, ligated proximally and distally, and excised. 
Animals received postoperative analgesia with buprenorphine (0.25  mg  kg–1). Hindlimb 
blood flow was quantified using a laser Doppler blood flow analyzer (Moor instruments) on 
postoperative days 0, 7, 14, and 21. Hindlimb blood flow is expressed as a percentage of is-
chemic to nonischemic limb blood flow.
Day 7 after surgery, gastrocnemius from both ischemic and nonischemic limbs was 
harvested under terminal anesthesia and fixed in 4% PFA for 1 hour at room temperature. 
Muscles were then embedded in Optimal Cutting Temperature compound (OCT) (Cellpath, 
KMA-0100-00A) and stored at –80°C until sectioned. Sections (10 µM) were taken using a 
Leica CM3050 S Research Cryostat.
Slides were blocked and permeabilized in PBS + 0.25% Triton-X100 + 1% BSA + for 1 
hour. Then stained with Isolectin B4-Alexa Fluor-488 (Invitrogen I21411) at 1/100 in PBS + 
0.25% Triton + 1% BSA for 1 hour. Slides were washed 3 times in PBS and mounted with a 
coverslip using Prolong Gold with DAPI (P36931, ThermoFisher). Slides were imaged using 
an LSM700 confocal microscope.
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Plasma samples
Blood samples were collected from the lateral saphenous vein (EDTA collection tubes 
Sarstedt 16.444). Samples were then spun at 10,000 RPM for 10 minutes in a bench top 
centrifuge. Plasma was stored at –20°C until used. IGFBP-1 (Abcam ab213865), IGFBP-2 
(Abcam ab207615), IGFBP-3 (R&D Systems, MGB300), insulin (Crystal Chem, 90080), and 
IGF-I (R&D Systems MG100) levels were measured as per kit instructions.
Protein expression
Tissue was harvested under terminal anesthesia and snap frozen. Tissue was homogenized 
and lysed in cell extraction buffer (FNN0011, Invitrogen, Carlsbad, CA) and protein content 
was quantified by a bicinchoninic acid assay (BCA) assay (Sigma-Aldrich, St. Louis, MO). 
Fifty micrograms of protein were resolved on a 4% to 12% Bis-Tris gel (Bio-Rad, Hemel 
Hempstead, UK) and transferred to nitrocellulose membranes. Membranes were probed 
with antibodies diluted in 5% BSA; 1:1000 AKT (cell signaling, #9272) [33], 1:1000 MAPK 
(Cell signaling, #4695) [34], and 1:20000 beta actin (Sc-47778; Santa Cruz) [35], before in-
cubation with appropriate secondary horseradish peroxidase-conjugated antibody [36, 37]. 
Blots were visualized with Immobilon Western Chemiluminescence HRP Substrate (Merck 
Millipore, Watford, UK) and imaged with Syngene chemiluminescence imaging system 
(SynGene, Cambridge, UK).
Recombinant full length human IGFBP-1 expression
Recombinant IGFBP-1 used in in vitro experiments was produced as previously described 
[17]. Briefly, the expression vector containing the DNA coding sequence of the mature 
human IGFBP-1 polypeptide was amplified from Image clone 4800940 and subcloned into 
pM-secSUMOstar vector. A mutant IGFBP-1 protein, unable to bind integrins, was created 
by altering the IGFBP-1 “RGD” motif sequence to WGD [38] using the Quikchange system 
(Agilent). An amino-terminal truncated coding sequence of IGFBP-1 lacking the IGF-I 
binding domain [39] was amplified by PCR from the IGFBP-1 cDNA clone using primers 
5′-ggggactcacgtctcgaggtctgccgggggagca-3′ (f) and 5′- gacagaacattatttcatctagattcagttttg
tac-3′ (r) and subcloned into pM-secSUMOstar vector as described for the full-length coding 
sequence. The SUMOstar coding sequence was fused to the amino terminus of truncated 
IGFBP-1 sequence (Leu 87 to Asn259 of the preprotein with a GlyGly linker between the 2 
sequences).
For protein expression, Expi293F cells (Life Technologies) were transiently transfected 
with the expression vector using Expifectamine as detailed by the manufacturer’s 
instructions, with medium harvested 7 days after transfection. After removal of cells and 
cell debris by centrifugation (10 minutes at 300g then 10 minutes at 4500g) and addition of 
protease inhibitor cocktail and phosphatase inhibitor cocktail 3 (both from Sigma), medium 
was passed through a 0.2-µm filter and protein was precipitated by addition of 2 volumes 
of saturated ammonium sulphate at 4°C followed by incubation on ice for 1 hour. After cen-
trifugation (4500g at 4°C for 1 hour) floating protein pellets were redissolved in Dulbecco’s 
PBS (DPBS) and residual ammonium sulphate was removed by gel filtration with DPBS-
equilibrated Zeba gel filtration spin columns (Fisher Scientific). His6SUMO–IGFBP-1 fu-
sion protein was then isolated using HisPur Cobalt spin columns (Fisher Scientific) as 
directed by the manufacturer’s instructions. Eluates were buffer-exchanged to DPBS using 
Zeba columns prior to digestion of His6SUMO–IGFBP-1 with SUMOstar protease. Cleaved 
His6SUMOstar was removed with HisPur Cobalt columns and eluant containing IGFBP-1 
was then applied to a Sephacryl S100 column equilibrated with DPBS at room temperature 
using an Akta Avant chromatography system (GE Healthcare). Purity was confirmed to 
≥95% by Coomassie staining of sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) gels. N-del mutant SUMO-IGFBP-1 was resistant to cleavage by SumoSTAR 
protease and was used as the intact fusion protein in experiments.
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Tube formation
Human umbilical vein endothelial cells (HUVECs) (Promocell, C-12203) were pre-treated 
for 24 hours with 500 ng/mL IGFBP-1 or PBS control or IGF-I neutralizing antibody (R 
and D systems AF-291-NA). Cells were washed once with PBS, trypsinized (Thermo fisher 
Scientific, 12604013) and resuspended in growth media (M199 (sigma, M4530), 20% FCS, 
20 mM HEPES, 1% AAS (Thermo fisher Scientific, 15240062), 15 µg/mL ECGS (Sigma, 
E2759), 2 mM Sodium Pyruvate, 5 U/mL heparin) and seeded at 100 000 cells per well of a 
Matrigel-coated (Beckton Dickinson, 734-0268) 24-well plate and incubated for 4 hours at 
37°C. Endothelial tube formation was evaluated as the mean number of tubes formed per 
high-power field (HPF) (×40).
Proliferation
HUVECS were seeded at 25,000 cells per well of a 24-well plate and left to settle overnight. 
HUVECs were pretreated for 1 hour with 500 ng/mL IGFBP-1 or PBS control and then used in 
a fluorescent EdU proliferation assay, as per kit instruction (Thermo fisher Scientific, C10337).
Cytodex bead
HUVECs were mixed with Cytodex 3 microcarriers (Amersham 17-0485-01) at a concen-
tration of 400 HUVECs per bead in 1 mL of growth media. Beads with cells were shaken 
gently every 20 minutes for 4 hours at 37°C and 5% CO2. After incubating, beads with 
cells were transferred to a 25-cm2 tissue culture flask and left overnight in 5 mL of media 
supplemented with rIGFBP-1 (500 ng/mL) at 37°C and 5% CO2. The following day, beads 
with cells were washed 3 times with 1 mL of media and resuspended at a concentration of 
200 cell-coated beads/mL in 2 mg/mL of fibrinogen (Sigma-Aldrich F-8630) with 0.15 units/
mL of aprotinin (Sigma-Aldrich A-1153), 5 ng/mL VEGF, and 5 ng/mL FGF. A total of 500 µL 
of fibrinogen/bead solution was added to 0.625 units of thrombin (Sigma-Aldrich T-3399) in 
1 well of a 24-well tissue culture plate. Fibrinogen/bead solution was allowed to clot for 5 
minutes at room temperature and then at 37°C and 5% CO2 for 20 minutes. One milliliter of 
media supplemented with rIGFBP-1 (500 ng/mL) was then added and incubation continued 
at 37°C and 5% CO2. Beads were imaged 24 hours later [40].
IGF-I ligand blot
The ability of rIGFBP-1 and mutant to bind IGF-I was assessed by ligand blotting using 
biotinylated IGF-I [41]. Purified recombinant IGF-I (R&D systems) was biotinylated 
with EZ-Link™ Sulfo-NHS-Biotin (Thermo) according to the manufacturer’s protocol. 
Protein samples containing IGFBP-1 were resolved by nonreducing SDS-PAGE then 
electrotransferred to PVDF membranes, blocked with 5% BSA in tris buffered saline (TBS)-T 
and probed with biotinylated IGF-I in TBS-T/5% BSA followed by Streptavidin-HRP (Cell 
Signalling Technologies) and chemiluminescent imaging was performed as described for 
western blot experiments.
Data analysis
All data are shown as the mean ± standard error of the mean (SEM). All image analysis 
was performed in ImageJ. Student unpaired t-test or analysis of variance were used where 
appropriate and performed with GraphPad Prism software version 7.
Data availability
The datasets generated during and/or analyzed during the current study are not publicly 
available but are available from the corresponding author on reasonable request.
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Results
Metabolic phenotype of IGFBP-1 knockout mice
To determine whether the presence of IGFBP-1 is essential for metabolic homeostasis 
and is implicated in physiological glucose regulation, we undertook detailed metabolic 
phenotyping in IGFBP-1-KO mice and their wild-type littermate controls. We first con-
firmed that IGFBP-1 was undetectable in the circulation of IGFBP-1-KO mice (Fig. 1A). 
IGFBP-1-KO mice had comparable body mass and wet organ weights to wild-type litter-
mate controls (Fig. 1B and C). Glucose homeostasis was unchanged in IGFBP-1-KO mice, 
as shown by comparable random plasma glucose levels, fasting glucose levels, glucose toler-
ance test, and area under the curve analysis to controls (Fig. 1D-G). Insulin sensitivity and 
insulin concentrations were also the same (Fig. 1H-J). The hypoglycemic response to IGF-I 
administration was comparable in IGFBP-1-KO mice and wild-type littermate controls 
(Fig. 1K). Total circulating IGF-I concentration was significantly increased in IGFBP-1-KO 
mice (Fig. 2A), but circulating levels of IGFBP-2 and IGFBP-3 were not different from wild-
type littermate controls (Fig. 2B and 2C). Expression of the metabolic signaling kinases 
AKT and MAPK in muscle and liver were no different between the genotypes (Fig. 2D–G). 
Accumulation of fat in the livers of IGFBP-1-KO mice, as shown by NAFLD scoring (Fig. 
1H), was unchanged.
Having excluded an obligatory role for IGFBP-1 in maintaining normal metabolism, we 
next investigated whether loss of circulating IGFBP-1 predisposes to obesity-induced glu-
cose intolerance and insulin resistance, as suggested by human observational data [9–11]. 
IGFBP-1-KO mice and their wild-type littermate controls were fed a 60% high-fat diet for 
8 weeks before metabolic profiling was performed. IGFBP-1-KO mice had comparable body 
mass to wild-type littermate controls after 8 weeks of high-fat feeding (Fig. 3A). Glucose 
homeostasis after 8 weeks of high-fat feeding was no different in the IGFBP-1-KO mice, as 
shown by fasting glucose levels, glucose tolerance test, and area under the curve analysis 
(Fig. 3B–D respectively). Insulin sensitivity was also no different between the 2 genotypes 
(Fig. 3E and 3F).
Vascular phenotype of IGFBP-1 knockout mice
We first examined whether IGFBP-1 is essential for normal vascular responses. Conduit 
artery vasomotor function in aortic rings ex vivo was comparable between IGFBP-1-KO 
mice and controls as shown by relaxation responses to acetylcholine (Ach) and constrictor 
responses to phenylephrine (PE) (Fig. 4A and 4B respectively). Having previously observed 
enhanced reparative capacity of the endothelium in IGFBP-1 overexpressing mice [16], 
we examined whether the presence of endogenous IGFBP-1 is necessary for effective re-
generation of wire-injured endothelium. IGFBP-1-KO mice had significantly impaired en-
dothelial regeneration 5  days after vascular injury compared with wild-type littermate 
controls (Fig. 4C and 4D). In recognition of the role of circulating inflammatory cells in vas-
cular repair and the role of the IGF axis in immune modulation, we examined the effect of 
IGFBP-1 deletion on circulating immune cells. There was no difference in circulating num-
bers of CD45+ cells, CD11b+ myeloid cells, neutrophils, monocytes, reparative monocytes, 
or inflammatory monocytes between IGFBP-1-KO and wild-type littermate controls (Fig. 
4E–J). However, there was a significant inflammatory monocyte skew in IGFBP-1-KO mice 
compared with wild-type littermate controls (Fig. 4K).
Deletion or overexpression of IGFBP-1 does not modulate angiogenesis in healthy mice
To investigate whether IGFBP-1 modulates physiological angiogenesis, we compared 
vascular architecture in the neonatal retina between p5 IGFBP-1-KO and IGFBP-1 
overexpressing mice and their respective wild-type littermate controls. There was no 
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Figure 1. Metabolic profiling of IGFBP-1-KO mice. (A) Plasma was taken from IGFBP- 
1-KO mice and wildtype litter mate controls, ELISA data confirmed IGFBP-1 knockdown 
(IGFBP-1-KO 0 ± 0 v Wt 5.69 ± 3.93 ng/mL). (B) Body mass was no different between  
groups (IGFBP-1-KO 22.8 ± 0.9 v Wt 23.1 g ± 0.9). (C) There was no difference in organ 
weights of IGFBP-1-KO mice when compared with wild-type litter mate control mice when 
normalized to body weight (Heart Wt 0.55 ± 0.04 v IGFBP-1-KO 0.56 ± 0.04) (Liver Wt  
4.9 ± 0.4 v IGFBP-1-KO 5.07 ± 0.04) (Spleen Wt 0.4 ± 0.08 v IGFBP-1-KO 0.39 ± 0.03)  
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difference in retinal vascular development between the IGFBP-1-KO and wild-type litter-
mate controls (Fig. 5A–G). Similarly, there was no difference in retinal vascular develop-
ment between IGFBP-1 overexpressing mice and wild-type littermate controls (Fig. 5H–M), 
although the number of filopodia per tip cell was higher in IGFBP-1 overexpressing mice 
(Fig. 5N).
To investigate whether IGFBP-1 influences pathological angiogenesis in response to is-
chemia due to arterial occlusion, IGFBP-1-KO and IGFBP-1 overexpressing mice and their 
respective wild-type littermate controls underwent femoral artery ligation. There was no 
difference in recovery of hindlimb perfusion, as assessed by laser Doppler imaging, between 
IGFBP-1-KO and wild-type litter mate (Fig. 6A and 6B) or between IGFBP-1 overexpressing 
mice and their wild-type littermate controls (Fig. 6C and 6D).
hIGFBP-1 overexpression improves recovery of perfusion following induction of hindlimb 
ischemia in insulin resistant mice
On the basis that a positive effect of IGFBP-1 on endothelial repair is only observed in 
insulin-resistant and not insulin-sensitive mice [16], we next investigated whether 
IGFBP-1 modulates angiogenesis in the setting of insulin resistance. We crossed IGFBP-1 
overexpressing mice with mice hemizygous for knockout of the insulin receptor (IRKO) that 
are known to be insulin resistant in the vasculature [42]. We first confirmed that IRKO 
mice had impaired recovery from hindlimb ischemia compared with wild-type littermate 
controls (Fig. 7A–D). Overexpression of human IGFBP-1 in IRKO mice ameliorated the 
detrimental effect of insulin resistance on recovery from hindlimb ischemia and vascular 
density in ischemic muscle (Fig. 7A–D).
rIGFBP-1 enhances endothelial cell angiogenic properties via IGF binding
To explore potential mechanisms by which IGFBP-1 positively modulates angiogenesis, 
we used HUVECs to investigate the proangiogenic effect of rIGFBP-1 in vitro. We em-
ployed Matrigel tube formation assays to mimic in vivo endothelial cell capillary forma-
tion. Incubation with rIGFBP-1 (500 ng/mL 24 hours) enhanced endothelial tube forming 
in HUVECs (Fig. 8A). To probe potential mechanisms behind IGFBP-1 enhanced tube for-
mation we investigated the effect of rIGFBP-1 on functional properties of endothelial cells. 
We used an 5-ethynyl-2’-deoxyuridine (EdU) incorporation assay to probe whether IGFBP-1 
enhances proliferation. After incubation with rIGFBP-1 for only 1 hour, endothelial cell 
proliferation was significantly enhanced (Fig. 8B). We then used a cytodex bead assay to de-
termine whether IGFBP-1 increases endothelial sprouting. HUVEC-coated beads grown in 
the presence of IGFBP-1 displayed a significantly increased number of sprouts and a trend 
for enhanced sprout length (Fig. 8C–E). We used site-directed mutagenesis and deletion 
to identify the structural motifs of rIGFBP-1 responsible for the proangiogenic effects. We 
first mutated the RGD domain to WGD to prevent interaction of rIGFBP-1 with cell surface 
(Kidney Wt 0.68 ± 0.05 v IGFBP-1-KO 0.6 ± 0.07) (WAT Wt 0.85 ± 0.07 v IGFBP-1-KO 0.9 ± 
0.2). (D) Random blood glucose was no different between groups (IGFBP-1-KO 10.4 ± 0.5 v 
Wt 10 ± 0.5). (E) Fasting blood glucose was no different between groups (IGFBP-1-KO 5.1 ± 
0.1 v Wt 5.6 ± 0.4). (F) Change in blood glucose levels after an IP injection of glucose, showed 
no difference in glucose handling, also shown by area under the curve analysis in G (IGFBP-
1-KO 41.3 ± 1.8 v Wt 41.6 AU ± 0.7). (H) Change in blood glucose levels after an IP injection 
of insulin, showed no difference in insulin sensitivity, also shown in area under the curve 
analysis in I: (IGFBP-1-KO 24.8 ± 3.1 v Wt 23.5 AU ± 1.9). (J) Random plasma insulin was 
no different between groups (IGFBP-1-KO 0.89 ± 0.18 v Wt 0.67 ± 0.24). (K) Change in blood 
glucose levels after an IP injection of IGF-I shows that IGFBP-1-KO mice was not signifi-
cantly different between the groups. Data are presented as mean ± SEM. N = 6 to 8 per group 
unless otherwise stated. (*P ≤ 0.05).
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Figure 2. Plasma levels and signaling nodes in IGFBP-1 knockdown mice. (A) Plasma was 
taken from IGFBP-1-KO mice and wild-type litter mate controls and there was an increase in 
circulating total IGF-I levels (IGFBP-1-KO 3257 ± 285.8 V Wt 2327 ± 77.61 ng/mL). N = 5 to 
7 per group for plasma samples. (B) Plasma was taken from IGFBP-1-KO mice and wildtype 
litter mate controls and there was no difference in circulating IGFBP-2 levels (IGFBP-1-KO 
1171 ± 44.09 V Wt 1292 ± 97.36 ng/mL) C: Plasma was taken from IGFBP-1-KO mice and 
wild-type litter mate controls and there was no difference in circulating IGFBP-3 levels 
(IGFBP-1-KO 557.8 ± 90.03 V Wt 495.3 ± 70.1). (D,E) There was no difference in AKT or 
MAPK expression in the muscle of IGFBP-1-KO mice when compared with their wild-type 
litter mate controls. (F,G) There was no difference in AKT or MAPK expression in the liver 
of IGFBP-1-KO mice when compared to their wildtype litter mate controls. N = 5 per group 
for blotting studies. (H) Histological examination of liver showed there was no difference in 
non-alcoholic fatty liver disease (NAFLD) score (Wt 1.8 ± 0.2 V IGFBP-1-KO 2 ± 0.3) (n = 4). 
Data are presented as mean ±SEM. (*P ≤ .05).
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integrin receptors. We also deleted the amino-terminal domain of rIGFBP-1 to prevent 
binding of IGFs. We observed enhancement of tube formation following pre-incubation with 
rIGFBP-1. There was a trend to increased tube formation compared with control despite 
WGD mutation, and the increase in tube formation was not significantly less than that seen 
with rIGFBP-1 stimulation, raising the possibility that the RGD domain is not involved in 
the angiogenesis effect seen. More work is needed however to fully understand the role of 
this domain (Fig. 8F). However, deletion of the N-terminus of IGFBP-1 (IGFBP-1 (ΔIGF-I)), 
which prevented IGF-I binding [43], obliterated its proangiogenic action (Fig. 8G). An es-
sential role for IGF-I in the modulation of angiogenesis by IGFBP-1 was confirmed by re-
peating these experiments with an IGF-I neutralizing antibody (Fig. 8H).
Discussion
In this report, we employed a loss of function approach to determine whether IGFBP-1 
has an obligatory role in metabolic and vascular homeostasis. We demonstrate that de-
letion of IGFBP-1 does not modulate metabolic phenotype in lean or obese mice, drawing 
into question the argument that low levels of IGFBP-1 are permissive for the develop-
ment of diabetes in humans. In the vasculature, we similarly demonstrated that deletion 
of IGFBP-1 does not affect conduit artery vasomotor responses. In contrast, the capacity 
for regeneration of injured vascular endothelium was significantly blunted in IGFBP-1-KO 
mice, indicating that IGFBP-1 does contribute to endogenous vascular repair. In animals 
with intact insulin signaling, neither deletion nor overexpression of IGFBP-1 modulates 
Figure 3. Metabolic profiling of IGFBP-1-KO obese mice. (A) Body mass was no different 
between groups (IGFBP-1-KO 38.8 ± 0.8 v Wt 40.8g ± 1.5). (B) Fasting blood glucose was 
no different between groups (IGFBP-1-KO 5.9 ± 0.44 v Wt 6.8 ± 0.55). (C) Change in blood 
glucose levels after an IP injection of glucose, showed no difference in glucose handling, also 
shown by area under the curve analysis in D (IGFBP-1-KO 49.6 ± 2 v Wt 51.6AU ± 2.2). (E) 
Change in blood glucose levels after an IP injection of insulin showed no difference in insulin 
sensitivity, also shown in area under the curve analysis in F (IGFBP-1-KO 26.76 ± 1.6 v Wt 
32.11AU ± 3.1). Data are presented as mean ± SEM. N = 6 to 8 per group. (*P ≤ .05).
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Figure 4. IGFBP-1 knockdown and endothelial function. (A) Relaxation responses to acetyl-
choline (Ach), expressed as percent reversal of phenylephrine induced contraction was the 
same between the genotypes. (B) Constrictor responses to PE was the same between the 
genotypes (N = 3–4). C: Representative in situ Evans blue staining 5 days after vascular 
injury (blue staining indicates denuded endothelium) in WT and IGFBP-1-KO mice (mag-
nification ×20) (Sham bottom). (D) Endothelial regeneration 5 days after vascular injury is 
reduced in IGFBP-1-KO mice when compared to litter mate controls (IGFBP-1-KO 62.82 ± 
4.5 V Wt 76.9 ± 2.1) (N = 4–6 per group). (E–J) There is no difference in CD45+ cells (IGFBP-
1-KO 2.59 ± 0.7 V Wt 4.78 ± 1.2 x106/mL), CD11b+ cells (IGFBP-1-KO 6.6 ± 0.56 V Wt 9.08 ± 
1.16 × 105/mL), neutrophil numbers (IGFBP-1-KO 3.3 ± 0.46 V Wt 3.8 ± 0.86 x105/mL), mono-
cyte cells (IGFBP-1-KO 2.4 ± 0.14 V Wt 3.37 ± 0.06 × 106/mL), reparative monocytes (IGFBP-
1-KO 1.023 ± 0.059 V Wt 1.75 ± 0.32 × 106/mL) or inflammatory monocytes (IGFBP-1-KO 
1.38 ± 0.08 V Wt 1.62 ± 0.33 × 106/mL) in IGFBP-1-KO mice when compared with controls. 
(K) There is a significant skewing of inflammatory to reparative monocytes IGFBP-1-KO mice 
when compared with controls (IGFBP-1-KO 1.32 ± 0.04 V Wt 0.96 ± 0.05) (n = 5). Data are 
presented as mean ± SEM. (*P ≤ .05).
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Figure 5. IGFBP-1 expression and developmental angiogenesis. (A–G) Retinas from 
IGFBP-1-KO mice p5 and wild-type litter mate controls were used to investigate the effects of 
IGFBP-1 knockout on developmental retinal angiogenesis. (A) Representative whole mount 
images. (B) There was no difference in vascular outgrowth (IGFBP-1-KO 1201 ± 165.4 V Wt 
1248 ± 62.55), (C) vessel density (IGFBP-1-KO 30.4 ± 5 V Wt 31.5 ± 3.2), or (D) branching 
complexity (IGFBP-1-KO 38.6 ± 3.2 V Wt 37.8 ± 6) between IGFBP-1-KO mice and wild-type 
litter mate controls. (E) Representative images of vascular front of retinas from IGFBP-1-KO 
mice and wild-type litter mate controls. (F) There is no difference between tip cell number 
(IGFBP-1-KO 2.3 ± 0.34 V Wt 2.1 ± 0.1) or (G) number of filopodia (IGFBP-1-KO 10.7 ± 0.95 
V Wt 9.3 ± 1. 78) between IGFBP-1-KO mice and wild-type litter mate controls (N = 4–5 per 
group). (H–N) Retinas from hIGFBP-1 overexpressing mice and wildtype litter mate controls 
were used to investigate the effects of hIGFBP-1 overexpression on retinal angiogenesis. (H) 
Representative whole mount images. (I) There is no difference in vascular outgrowth between 
IGFBP-1-tg mice and wildtype litter mate controls (tg 1579 ± 58.4 V Wt 1456 ± 55.6). (J) 
There is no difference in vessel density between IGFBP-1-tg mice and wild-type litter mate 
controls (tg 24.3 ± 2 V Wt 23.9 ± 1.4). (K) There is no difference in branching complexity 
between IGFBP-1-tg mice and wild-type litter mate controls (tg 28.4 ± 2.3 V Wt 31 ± 2.2). 
(L) Representative vascular front images. (M) There is no difference between tip cell number 
between IGFBP-1-tg mice and wild-type litter mate controls (tg 2 ± 0.18 V Wt 2.1 ± 0.21). 
(N: There is an increase in number of filopodia (white arrow head) in IGFBP-1-tg mice when 
compared with wild-type litter mate controls (tg 13 ± 1.1 V Wt 8 ± 0.66). N = 5 to 7 per group. 
Data are presented as mean ± SEM.
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angiogenesis. However, in insulin-resistant mice increasing IGFBP-1 does positively influ-
ence recovery of perfusion following induction of hindlimb ischemia. At the cellular level, 
IGFBP-1 stimulated endothelial proliferation and sprouting though a molecular mechanism 
dependent on IGF-I but not RGD ligation.
Clinical data from diverse populations suggest that low levels of IGFBP-1 may be per-
missive for the development of type 2 diabetes in humans [6, 7, 10, 11]. In a population-
based study of individuals of European or Pakistan origin, IGFBP-1 was independently 
associated with impaired 2-hour glucose tolerance and every 2.7 ng/mL increase in IGFBP-1 
was associated with a 40% risk reduction for developing impaired glucose tolerance [6]. 
Figure 6. IGFBP-1 expression and pathological angiogenesis. (A,B) Mice with IGFBP-1 
knock down were used to investigate recovery from hind limb ischemia as a model of patho-
logical angiogenesis. (A) Representative laser Doppler perfusion images of mouse hind limbs 
on day 0, 7, and 14 after injury. (B) Quantitative analysis of the perfusion recovery measured 
by laser Doppler. The index was calculated as the ratio of ischemic to nonischemic hind limb 
perfusion. There is no difference in IGFBP-1-KO mice compared with wild-type litter mate 
controls There was no difference in necrotic toes between the genotypes (data not shown). 
N = 6 to 8 per group. (C,D) Mice overexpressing hIGFBP-1 were used to investigate recovery 
from hind limb ischemia. (C) Representative laser Doppler blood perfusion images of mouse 
hind limbs on day 0, 7, and 14 after injury. (D) Quantitative analysis of the perfusion recovery 
measured by laser Doppler. The index was calculated as the ratio of ischemic to non-ischemic 
hind limb blood perfusion. There was no difference in necrotic toes between the genotypes 
(data not shown) N = 7.
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A similar population study in healthy pubertal children, identified a strong positive corre-
lation between IGFBP-1 and insulin sensitivity and an inverse correlation with body mass 
[7]. In a prospective study with 17 years of follow-up, low IGFBP-1 levels strongly predicted 
the long-term development of type 2 diabetes [11]. Although persuasive in supporting the 
argument that low levels of IGFBP-1 serve as a driver for the development of metabolic 
Figure 7. IGFBP-1 over expression in IRKO mice which have impaired hind limb ischemia 
recovery. (A–D) IRKO mice were used as a model of insulin resistance to investigate the ef-
fects on hind limb ischemia recovery. (A) Representative laser Doppler blood perfusion images 
of mouse hind limbs on day 0, 7, 14, and 21 after injury. (B) Quantitative analysis of the per-
fusion recovery measured by laser Doppler. The index was calculated as the ratio of ischemic 
to non-ischemic hind limb blood perfusion. There is significant impaired recovery in IRKO 
mice compared with wild-type litter mate controls at day 7 post surgery (IRKO 19.1% ± 2.3 V 
Wt 27.8% ± 4.6) and also shown in area under the curve in C (IRKO 77.8 ± 6.1 V Wt 108.6 ± 
11 v IRKOxIGFBP-1-Tg 116.2 ± 13.7). IGFBP-1 overexpression improves recovery when com-
pared to IRKO wild-type litter mate controls, as shown in area under the curve (IRKO 77.7 ± 
6.1 V IGFBP-1 × IRKO 116.2 ± 13.7). (D) Gastrocnemius from ischemic and nonischemic 
limbs were stained with isolectin B4 (red) as a marker of endothelial cells and DAPI (blue) 
as a nuclear stain and capillary density quantified (Wt 17 ± 2 V IRKO 5.8 ± 2.1 V IRKO × 
IGFBP-1-Tg 15.03 ± 5.3) N = WT 6, IRKO 12, and IGFBP-1 × IRKO 19. Data are presented 
as mean ± SEM. (*P ≤ .05).
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Figure 8. IGFBP-1 and angiogenic properties in vitro. (A) HUVECs were used to investi-
gate the effects of rIGFBP-1 on endothelial cell tube formation on Matrigel. Treatment with 
rIGFBP-1 for 24 hours before being seeded onto Matrigel enhanced endothelial cell tube 
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disorders, such studies cannot prove a causal role for IGFBP-1. We previously reported 
that increased levels of IGFBP-1 promote insulin sensitivity and improve glucose tolerance 
[15, 17]. These findings indicate that increasing IGFBP-1 may be useful as a therapeutic 
strategy, but do not answer the question of whether IGFBP-1 plays an obligatory part in 
normal physiology and whether its loss is harmful.
To address whether IGFBP-1 has an essential role in metabolic and vascular physi-
ology, we extended our previous “gain-of-function” studies by performing “‘loss-of-function” 
investigations reported here. We found that deletion of IGFBP-1 did not materially affect 
metabolic phenotype in mice. Results of glucose tolerance, insulin tolerance, and IGF-I tol-
erance tests were similar in mice lacking IGFBP-1. Failure of IGFBP-1 deletion to alter 
metabolic phenotype suggests that IGFBP-1 is not essential for normal metabolic physi-
ology, and that loss of IGFBP-1 activity is not causally implicated in susceptibility to dia-
betes of humans with low IGFBP-1 levels. Instead, IGFBP-1 may be acting as a biomarker 
for insulin sensitivity as previously suggested [7]. However, there are some caveats to 
this interpretation. Genetic deletion studies in knockout animals may be confounded by 
upregulation of other bioactive molecules in compensatory or adaptive responses. Plasma 
levels of IGFBP-2 and IGFBP-3 were comparable between IGFBP-1-KO mice and their 
wild-type littermate controls, implying that the IGFBP-1 knockdown did not result in a com-
pensatory increase in either of these IGFBPs which are known to be implicated in glucose 
regulation [44–48]. However, we cannot exclude altered levels of other bioactive molecules. 
We did find, consistent with previous reports, that IGFBP-1-KO mice had higher total IGF-I 
levels [49]. As IGF-I promotes insulin sensitivity [50], this increase in circulating IGF-I may 
compensate for the lack of IGFBP-1 and explain why IGFBP-1-KO do not display impaired 
glucose tolerance or insulin resistance in line with population data in the literature. It is 
also worth noting that mouse physiology does not completely reflect the human situation 
and this could be a possible explanation for the lack of effect of IGFBP-1 deletion on met-
abolic parameters. However, our results are consistent with the findings of a prospective 
study of 615 normoglycemic men and women [10], in which total IGF-I concentrations were 
inversely associated with subsequent 2-hour glucose concentrations, but only in people with 
low concentrations of IGFBP-1, suggesting that the biological interaction between IGF-I 
and IGFBP-1 is important in glucose homoeostasis.
Several studies have shown that IGFBP-1 levels are correlated with BMI, raising the 
possibility that IGFBP-1 is implicated in obesity [3, 6–8]. To investigate if loss of IGFBP-1 
predisposes to obesity-related glucose intolerance and insulin resistance, we challenged 
IGFBP-1-KO mice and their wild-type littermate controls with a 60% high-fat diet for 8 
formation when compared to unstimulated cells (IGFBP-1 40 ± 4.26 V UN 26.75 ± 1.98). 
(B) HUVECs were used to investigate the effects of rIGFBP-1 on endothelial cell prolifer-
ation using an EDU incorporation assay. Treatment with rIGFBP-1 for 1hr before EdU was 
added enhanced endothelial cell proliferation when compared to unstimulated cells (IGFBP-1 
15.24 ± 1.8 V UN 7.23 ± 1.67). (C) HUVECs were used to investigate the effects of rIGFBP-1 
on endothelial cell sprouting using a cytodex bead assay. Representative images are shown. 
Beads were either grown in the presence of IGFBP-1 or not. (D) Beads grown in the pres-
ence of IGFBP-1 had a significantly increased number of sprouts (IGFBP-1 13.2 ± 0.79 V UN 
10.7 ± 0.75). (E) Beads grown in the presence of IGFBP-1 had a trend for enhanced sprout 
length (IGFBP-1 2.7 ± 0.28 V UN 2.1 ± 0.23). (F) HUVECs were used to investigate the 
effects of mutant IGFBP-1 on endothelial cell tube formation on Matrigel. Treatment with 
WGD mutant IGFBP-1 for 24 hours before being seeded onto Matrigel had no effect on endo-
thelial cell tube formation when compared with IGFBP-1 treated cells (IGFBP-1 37.2 ± 4.3 V 
WGD 30.6 ± 4.6). G: Treatment with amino-terminal deletion mutant IGFBP-1 for 24 hours 
before being seeded onto Matrigel reduced endothelial cell tube formation when compared 
with IGFBP-1 cells (IGFBP-1 37.18 ± 4. V NDEL 19.05 ± 1.3). (H) Treatment with an IGF-I 
neutralizing antibody and IGFBP-1 for 24 hours before being seeded onto Matrigel reduced 
endothelial cell tube formation when compared to IGFBP-1 only treated cells (IGFBP-1 69.3 ± 
5.1. V IGF-1ab + IGFBP-1 38.7 ± 9.8). Data are presented as mean ± SEM. (*P ≤ .05; **P ≤ 
.01). N = 4 per group.
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weeks. After high-fat feeding, IGFBP-1-KO mice had comparable body mass, glucose ho-
meostasis, and insulin sensitivity, indicating that IGFBP-1 is not causally implicated in 
protection from obesity and obesity-impaired glucose tolerance.
We next investigated if loss of IGFBP-1 influences vascular function, recognizing that 
several studies report a negative correlation between IGFBP-1 and biomarkers of cardi-
ovascular disease such as blood pressure, BMI, waist/hip ratio, and fasting insulin levels 
[6–8]. Furthermore, in a prospective study, it was found that low baseline levels of IGF-I 
and IGFBP-1 increased the risk of fatal ischemic heart disease among both elderly men 
and women independent of prevalent ischemic heart disease and other cardiovascular risk 
factors [12]. In contrast to the positive influence of IGFBP-1 on vascular phenotype, we 
reported in gain-of-function studies previously, in which IGFBP-1 increased endothelial ni-
tric oxide generation [15], in the current dataset aortic vasomotor function was not altered 
by deletion of IGFBP-1. This implies that IGFBP-1 does not play a critical role in mainte-
nance of normal vasomotor physiology. However, it should be recognized that both IGFBP-1 
and IGF-I stimulate nitric oxide generation and have been shown to reduce atherosclerosis 
in mice [15, 26]. We speculate that in relation to endothelial function, increased IGF-I is 
compensating for loss of IGFBP-1 in IGFBP-1-KO mice.
IGFBP-1 is required for the endothelium to respond appropriately to injury. Following 
wire injury to the femoral artery, recovery of endothelial coverage was significantly impaired 
in IGFBP-1-KO compared with wild-type controls. As discussed further below, we found 
that IGFBP-1 significantly upregulates endothelial cell proliferation, the loss of which may 
contribute to deficient repair in knockout animals. Additionally, endothelial regeneration 
is influenced by cell types other than endothelial cells, not least circulating inflammatory 
cells [51]. Although total abundance of monocytes was unaltered by IGFBP-1 deletion, we 
observed that the ratio of inflammatory to reparative monocytes was adversely skewed 
in IGFBP-1-KO mice. Further work is required to determine whether adverse monocyte 
skewing predisposes IGFBP-1-KO to impaired endothelial regeneration [52]. Diminished 
capacity for endothelium to regenerate in response to mechanical or biochemical injury 
contributes to adverse vascular remodeling and atherosclerosis [53]. Loss of this capacity in 
individuals with low IGFBP-1 levels may therefore be implicated in increased vascular risk 
and predisposition to macrovascular disease [13, 54].
Angiogenesis is a tightly regulated process that is vital during postnatal development 
and contributes to several pathologies including cancer and response to ischemia arising 
from occlusive vascular disease. Members of the IGFBP family have been ascribed posi-
tive and negative roles in angiogenesis which are actioned both through their binding to 
IGFs and through IGF-independent mechanisms [19]. Although modulatory effects on an-
giogenesis have been well documented for some of the IGFBPs, little is known about the 
angiogenic properties of IGFBP-1. We addressed this by carrying out loss-of-function and 
gain-of-function studies in vivo. Vascular patterning in the postnatal retina remained intact 
in IGFBP-1-KO mice, indicating that IGFBP-1 is not essential in developmental angiogen-
esis. Because the cellular processes and microenvironmental cues implicit in endothelial re-
generation and sprouting angiogenesis differ, it is not surprising that the effect of IGFBP-1 
on these readouts may diverge. Similarly, retinal vascular architecture was not materially 
affected by IGFBP-1 overexpression, although increased numbers of filopodia were observed 
in tips cells of IGFBP-1 overexpressing mice. Filopodia are thought to drive directional mi-
gration of tip cells in response to microenvironmental cues [55]; however, the relevance of 
increased numbers of filopodia in IGFBP-1-tg retinas in the absence of altered radial out-
growth is uncertain.
Neovascularization in response to ischemia in adult animals contributes to tissue per-
fusion in occlusive vascular disorders and has been targeted for exploitation clinically 
in therapeutic angiogenesis [19]. In mice with intact insulin signaling, neither IGFBP-1 
knockout nor overexpression altered recovery of tissue perfusion after induction of hindlimb 
ischemia. This suggests that IGFBP-1 does not possess an obligatory role in pathological 
angiogenesis and increasing circulating IGFBP-1 is unable to augment the response to 
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ischemia, at least in “metabolically normal” animals. However, angiogenic responses in 
young metabolically healthy animals are likely to be optimal with limited opportunity to be 
augmented further. To investigate whether elevated IGFBP-1 levels could promote recovery 
from hindlimb ischemia in a “disease” model, we crossed IGFBP-1 overexpressing mice with 
IRKO mice, which are hemizygous for knockout of the insulin receptor. IRKO mice display 
several phenotypic properties consistent with prediabetes in humans, including mild in-
sulin resistance, endothelial dysfunction, and elevated blood pressure, and have impaired 
regeneration following arterial injury and impaired recovery from hindlimb ischemia [42, 
56, 57]. In contrast to mice with intact insulin signaling, overexpression of IGFBP-1 in 
IRKO mice restored limb perfusion after induction of ischemia to normal levels observed 
in wild-type mice. This implies that IGFBP-1 can promote neovascularization in insulin-
resistant animals but not in healthy animals with normal metabolism. We observed that 
IGFBP-1 has direct proangiogenic effects on endothelial cells in vitro, stimulating prolif-
eration, sprouting, and tube formation. Given that insulin resistance was not modelled in 
vitro for these experiments, we deduce that IGFBP-1 is an inherently proangiogenic protein 
which lacks capacity to promote neovascularization in healthy animals but has angiogenic 
properties which are unmasked when animals are challenged by insulin resistance.
Our results provide novel insights into the molecular mechanisms by which IGFBP-1 
stimulates angiogenesis and indicate that these are not IGF independent. Intriguingly, we 
discovered that ablation of the ability of IGFBP-1 to interact with cell surface integrins 
by site-directed mutagenesis of the RGD domain did not significantly impair its capacity 
to stimulate endothelial tube formation. This contrasts with the mechanisms by which 
IGFBP-1 stimulates nitric oxide generation in endothelium or increases insulin signaling 
in skeletal muscle, both of which are RGD domain dependent [16, 17]. Instead, upregulation 
of angiogenesis by IGFBP-1 was abrogated by preventing IGF-I binding or by inhibiting 
IGF-I with a blocking antibody. The mechanisms by which IGFBP-1 and IGF-I cooperate to 
promote angiogenic responses in endothelium require further investigation.
Conclusions
In summary, the loss of function studies in IGFBP-1-KO mice reported here suggest that 
IGFBP-1 does not play an essential role in metabolic or vascular physiology. This draws 
into question the concept that low levels of IGFBP-1 are permissive for the development 
of cardiometabolic disease in humans. An important caveat is that total IGF-I levels were 
increased in IGFBP-1-KO mice, which prevents us from modelling the influence of low IGF-I 
and low IGFBP-1 in combination that is known to be associated with glucose intolerance 
in humans. Interestingly, IGFBP-1 was required for normal regeneration of endothelium, 
raising the possibility that IGFBP-1 deficiency may expose humans to vascular disease 
by reducing capacity for the endothelium to repair in response to injury. Finally, IGFBP-1 
displays promise for therapeutic angiogenesis, as a pro-angiogenic protein with ability to 
increase perfusion in tissue ischemia in the setting of insulin resistance.
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